ClinicalTrials.gg
RecruitingNCT06244355PNN-CPUpdated Mar 6, 2026

Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer

An observational study in Lung Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, none of them phase 3. Lung Neoplasms · Assistance Publique - Hôpitaux de Paris.

Started
2024
with 1 other
Observational
7 of 19
4 open now
Registered
16th of 19
by date

Among the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2024, is one of 7 observational ones, and was the 16th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The objective is to study the phenotypic, functional and metabolomic characteristics of neutrophils circulating subpopulations in lung cancer patients, and to compare them to a control group of healthy volunteers. A blood sample will be taken before the first treatment session for the lung cancer patient and a second blood sample will be taken during the first evaluation visit.

The investigators hypothesize that there may be different circulating neutrophil subpopulations in patients with metastatic non-small cell lung cancer (NSCLC) involved in tumor progression and resistance to immunotherapy.

Read the detailed description

Immune checkpoint inhibitors (ICI) have been shown to be effective in metastatic lung cancer. Unfortunately, 80% of patients do not respond and show rapid disease progression. Identifying predictive biomarkers of response is essential for early adaptation of management. Circulating lymphocytes and neutrophils represent a biomarker (NLR), predictive of immunotherapy response, in particular via the measurement of the neutrophils /lymphocyte ratio. Some preclinical work suggests a role for circulating neutrophil subpopulations like MDSC (myeloid derived suppressor cells) in ICI resistance. Certain circulating neutrophil subpopulations are thought to promote tumor progression, angiogenesis and metastasis with immunosuppressive activity. Identifying these pro-tumor subpopulations could predict the response to ICI and could be a potential therapeutic target. Our goal is to characterize the circulating neutrophil subpopulations of lung cancer patients and correlate these characteristics with response and survival phenotypically and functionally.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Neutrophils
  • neutrophil subsets
  • Advanced lung cancer
  • biomarkers
  • PD-1 immunotherapy
  • Chronic inflammation
  • Phenotypic modulation
  • Spectral cytometry
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with metastatic lung cancer, without anterior treatment. Inclusion during a consultation or hospitalization by a pneumologist or oncologist in the thoracic oncology unit during care.

Eligibility criteria

Inclusion Criteria common to lung cancer and patients :

  • Age ≥ 18 years,
  • male or female,
  • affiliated with a Health Insurance,

Inclusion Criteria for lung cancer patients :

- Diagnosis of stage lung cancer with mutation status, naïve treatment

Inclusion Criteria for COPD patients :

- Diagnosis of COPD post-smoking

Exclusion Criteria:

  • Tuberculosis or other acute or chronic bacterial infections
  • Chronic progressive viral infections ( and C, )
  • Previous or ongoing chemotherapy
  • Impossibility of giving the subject informed information.
  • Opposition to the research.
  • Participation in another research study with an exclusion period still in progress at pre-inclusion (possible inclusion in an observational study)
  • Vulnerable individual (pregnant, parturient or breastfeeding woman), persons under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision)
  • Patients benefiting from the AME
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Lung cancer

    Metastatic, with complete mutational status, without anterior treatment

    Other: Extra blood tubes

  • Chronic obstructive pulmonary disease (COPD)

    Diagnosis of post-smoking COPD (without diagnosis of CP)

    Other: Extra blood tubes

  • Healthy volunteers

    Healthy volunteers (based on biological and clinical data already available from the partner)

    Other: Extra blood tubes

Interventions

  • OtherExtra blood tubes

    Extra blood tubes

06

What researchers measure

Primary outcomes

  1. Presence of a subpopulation of circulating neutrophils

    Presence of a subpopulation of circulating neutrophils in patients with lung cancer (absent in healthy volunteers and COPD patients) with phenotypic CD45+, CD15+, CD16+, CD62L-, LOX1+ and functional immunosuppressive characteristics.

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. Demographic characteristics

    Demographic characteristics : age, sex and smoking

    Time frame: Day 1

  2. Performans status

    Somatic characteristics

    Time frame: Day 1

  3. Stage

    Somatic characteristics

    Time frame: Day 1

  4. Histologic type

    Histologic characteristics

    Time frame: Day 1

  5. Mutation status

    Molecular characteristics

    Time frame: Day 1

  6. Clinical assessment

    Progression free survival (defined as the time between the start of treatment and the date of first observation of clinical or CT progression (irRECIST1.1 criterion) or death)

    Time frame: Up to the end of participation, between month 3 and month 4

  7. irRECIST 1.1 response

    CT scan to evaluate progression free survival (defined as the time between the start of treatment and the date of first observation of clinical or CT progression (irRECIST1.1 criterion) or death)

    Time frame: Up to the end of participation, between month 3 and month 4

  8. Death

    Progression free survival (defined as the time between the start of treatment and the date of first observation of clinical or CT progression (irRECIST1.1 criterion) or death)

    Time frame: Up to the end of participation, between month 3 and month 4

  9. Mortality

    Overall survival (defined as the time from treatment diagnosis to the date of death).

    Time frame: Up to the end of participation, between month 3 and month 4

07

Study locations

1 of 1 sites recruiting
  • Assistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospital - Pneumology unit
    Paris, Île-de-France Region 75014, France
    Recruiting
    • Marie WISLEZ, Pr · Contactmarie.wislez@aphp.fr · +33 1 58 41 18 89
    • Marie WISLEZ, Pr · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jun 2027, 40 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 40 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Feb 6, 2024
StartActual
Feb 12, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06244355
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Feb 6, 2024
Start date
Feb 12, 2024
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 6, 2026

Study contacts

Marie WISLEZ, Pr
Contact
marie.wislez@aphp.fr
+33 1 58 41 18 89
Marie BENHAMMANI-GODARD
Contact
marie.godard@aphp.fr
+33 1 58411190
Marie WISLEZ, Pr
principal investigator · Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion